Introduction
============

Shivering is a common post-anesthetic complication occurring in up to 56.7% of patients undergoing spinal or epidural anesthesia. Shivering may interfere with electrocardiogram, blood pressure, and oxygen saturation monitoring. In addition, shivering increases oxygen consumption, carbon dioxide production, and metabolic rate by up to 400%. Thus, it may result in problems in patients with low cardiac and pulmonary reserves \[[@B1]-[@B3]\]. Preventing shivering could therefore result in better postoperative outcomes or reduce the incidence of post-surgical complications.

Magnesium sulfate (MgSO~4~) has anti-shivering effects. Moreover, it has potential neuroprotective effects, and may enhance neuroprotection against the effects of hypothermia \[[@B1],[@B3]-[@B9]\]. Intrathecal MgSO~4~ administration provides effective perioperative analgesia and can prolong the period of anesthesia and sensory blockade without any additional side-effects \[[@B4]-[@B10]\]. However, most of the research on the role of MgSO~4~ in the prevention of shivering has focused on intravenous infusion of this drug \[[@B11],[@B12]\]. Few clinical trials have examined the effect of adding intrathecal MgSO~4~ to anesthetic agents such as bupivacaine to suppress anesthesia-related shivering in patients.

Similar to infusion studies, we hypothesized that the addition of intrathecal injection of MgSO~4~ to bupivacaine would improve perioperative shivering in female patients undergoing elective caesarean section. Few previous studies evaluated neuroaxial anti-shivering effects of intrathecal magnesium and none evaluated the anti-shivering effect of intrathecal MgSO~4~. Therefore, we elected to use the lowest dosage (25 mg MgSO~4~) that was formerly utilized for investigation of analgesic effects \[[@B5],[@B7],[@B10]\].

Materials and Methods
=====================

In a randomized, double-blinded controlled trial, 72 patients in an academic general hospital between June 2011 and March 2012 were enrolled in the study. The patients were selected by block randomization into two groups. The inclusion criteria were as follows: 18-37 years of age and American Society of Anesthesiologists (ASA) physical status I-II who were scheduled for elective repeat cesarean section under spinal anesthesia. The exclusion criteria were as follows: ASA physical status \> II, obesity (body mass index \> 30 kg/m^2^), preoperative temperature \> 38℃, any contraindications to regional anesthesia, allergy to the study drugs, pre-eclampsia, alcohol or substance use, neuropathies, respiratory distress, coagulopathies, and any possible thermoregulation altering medications. The hospital Ethics Committee approved the study protocol and written informed consent was obtained from all participants.

Operating room temperature was maintained at 23-25℃ with a humidity of 55-65%. No other warming device was used. Intravenous fluids fluids were preheated at room temperature. All patients were covered with one layer of surgical drapes over the chest, thighs, and calves during the operation, and one cotton blanket over the entire body postoperatively. Before administering spinal anesthesia, standard monitoring was established and patients were given 10 ml/kg lactated Ringer\'s solution intravenously over 30 min.

Spinal anesthesia was administered in the left lateral decubitus position at the L4-L5 interspace. All participants received 2 ml of 0.5% bupivacaine (Mylan, 20 mg/4 cc) using a Quincke spinal needle (K-3 Point, 25 G, 90 mm, Dr.Japan, Co., Tokyo, Japan). The syringes were prepared by a separate colleague and the anesthetist was not aware of the contents. In the treatment group, 2 ml of 0.5% bupivacaine plus 25 mg MgSO~4~ (MgSO~4~ 5% diluted to 25 mg/0.5 ml, Samen daru, Iran) were injected intrathecally. In the control group, 2 ml of 0.5% bupivacaine plus 0.5 ml normal saline were injected intrathecally. All variables were recorded by a different colleague who was not aware of the group allocation. Core temperature was measured using an infrared tympanic electronic thermometer (Genius II, Covidien, Mansfield, MA, USA). Heart rate (HR) was measured by ECG monitoring. Systolic and diastolic blood pressures were measured by non-invasive blood pressure, and oxygen saturation by pulse oximetry. Vital signs were assessed every 5 min for the first 15 min and every 10 min thereafter until the end of recovery. Temperature measurements were performed before the spinal block, immediately after the spinal anesthesia, and then every 30 min until 1 h after entry into the post-anesthesia care unit.

Shivering was measured at the following time points: immediately after spinal anesthesia, and at 5, 10, 15, 20, 30, 40, 50, 60 and 90 min later. Shivering was graded where 0 (none) = no visible shivering or muscular tonicity; 1 (mild) = mild increase in masseter or face muscle tonicity; 2 (moderate) = tremor or muscular tonicity in proximal muscles; and 3 (severe) = tremor or muscular tonicity involving the whole body \[[@B13]\].

Sedation was graded using the Ramsay sedation scale, in which 1 = patient was anxious, agitated or restless; 2 = patient was co-operative, oriented, and tranquil; 3 = patient responded to commands only; 4 = patient exhibited a brisk response to light glabellar tap or loud auditory stimulus; 5 = patient exhibited a sluggish response to light glabellar tap or loud auditory stimulus; and 6 = patient exhibited no response \[[@B14]\]. In cases where shivering scores were greater than or equal to 3, 25 mg meperidine was administered intravenously. If the heart rate was less than 50 beats per min, 0.5 mg atropine was administered. Also, if the systolic arterial pressure was less than 90 mmHg, an intravenous dose of 10 mg ephedrine was administered.

Results were reported as means ± standard deviation (SD) for quantitative variables and percentages for categorical variables. The groups were compared using Student\'s t-test for continuous variables and the chi-square test (or Fisher\'s exact test if appropriate) for the categorical variables. Trends in the changes in vital signs during the study were assessed using the trend for chi-square test. P values of 0.05 or less were considered to indicate statistical significance. All statistical analyses were carried out using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.1 for Windows (SAS Institute Inc., Cary, NC, USA).

Results
=======

A total of 72 females with a mean age of 26.74 ± 3.87 (range 20-37 years), were considered for admittance into the study. They were randomized into two groups: 1) administered MgSO~4~ or 2) normal saline. The two groups had similar characteristics with regard to age, body mass index, sensory block onset and duration, blood loss, and duration of surgery ([Table 1](#T1){ref-type="table"}). Cardio-respiratory indices including systolic and diastolic blood pressures, heart rate, and SpO~2~ between the groups at various time points after blocking were similar (P \> 0.05) ([Fig. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

No significant intergroup differences in appearance of shivering were seen immediately, or at 5, 30, 40, 50, 60, and 90 min after block administration. However, after 10, 15, and 20 min, there was a significant difference (P \< 0.05) between the groups. The group administered MgSO~4~ exhibited lower shivering grades compared with the control group. No differences between the groups in the grade of sedation were observed at various time points after blocking ([Table 2](#T2){ref-type="table"}). Core temperature was significantly reduced in the MgSO~4~ group compared to the normal saline group 30 min after blocking ([Fig. 3](#F3){ref-type="fig"}). None of the patients in the MgSO~4~ group needed meperidine. However, 25-mg meperidine was administered intravenously to eight patients (22.2%) in the control group; the difference was statistically non-significant (P = 0.07).

Discussion
==========

Shivering may interfere with intraoperative monitoring devices and increases oxygen consumption, carbon dioxide production and lactic acidosis \[[@B3]\]. Research has demonstrated the effectiveness of intravenous infusion of MgSO~4~ in shivering control after regional anesthesia. Therefore, we evaluated its intrathecal effects in this study. There are also beneficial effects of the addition of MgSO~4~ to anesthetic drugs, including improving intraoperative conditions, prolongation of analgesia duration, and minimizing clinical drug-related side effects such as nausea, pruritis, and somnolence \[[@B15]-[@B18]\]. Indeed, MgSO~4~ infusion can prevent shivering during transurethral prostatectomy and lower limb surgeries in patients receiving spinal anesthesia \[[@B3],[@B7]\]. However, the current study is the first to determine the effect of adding intrathecal MgSO~4~ to bupivacaine in patients undergoing caesarean section.

The main finding of this study is that in patients undergoing caesarean with spinal anesthesia, the addition of MgSO~4~ intrathecally effectively reduced shivering within 10 to 20 min after block administration. This effect, however, did not persist thereafter. Considering these findings, we presume that the injection of 2 ml of 0.5% bupivacaine plus 25 mg MgSO~4~ intrathecally is not a sufficient dose to achieve a continuous or longer duration of anti-shivering effects. Interestingly, the shivering scores were lower in both groups after 20 min ([Table 3](#T3){ref-type="table"}).

Haulbold and Meltzer \[[@B19]\] reported sensorial and motor blockades in humans after intrathecal administration of magnesium. Furthermore, recent studies have demonstrated that the administration of magnesium intrathecally is safe and in combination with other anesthetic agents extends the effects of spinal anesthesia in both animal and human models \[[@B20]\]. The beneficial effects of MgSO~4~ on preventing post-anesthetic shivering, however, remain unclear. Despite the investigation of multiple drug regimens in prevention of postoperative shivering, the ideal treatment has not yet been determined. Some of these agents are as follows: meperidine, tramadol, fentanyl, physostigmine, clonidine, and ketamine \[[@B1],[@B21]-[@B26]\]. Because the incidence of hypotension, sedation and other side effects is relatively significant following use of these drugs, administration to reduce shivering may not be ideal. Consequently, the use of regional MgSO~4~ is attractive for this purpose.

The mechanism of shivering during regional anesthesia is not understood. Some possibilities include a temporary halt in central thermoregulation \[[@B1],[@B23],[@B24]\] and internal redistribution of body heat lost to the environment \[[@B25]\]. Furthermore, MgSO~4~ use can cause peripheral vasodilatation, which potentially improves coetaneous circulation, thus decreasing the incidence of shivering \[[@B10]\]. Moreover, MgSO~4~ acts as a calcium antagonist and a non-competitive antagonist of N-methyl-D-aspartate receptors, and its effect on analgesia, particularly neuropathic pain symptoms and motor blockade lengthening, has been reported \[[@B3],[@B15],[@B27]\]. This mechanism of action has also been considered for the anti-shivering effects of magnesium, but requires further investigation in animal models and clinical studies.

In the current study, we also report that core temperature was reduced in the MgSO~4~ group 30 min after block administration. Indeed, injection of MgSO~4~ is known to result in reduction of core temperature following anesthesia. Gozdemir et al. \[[@B3]\] reported that MgSO~4~ infusion prevented shivering in patients receiving spinal anesthesia, but increased the risk of hypothermia. In the Wadhwa et al. \[[@B28]\] study, magnesium significantly reduced the shivering threshold. However, it could not induce hypothermia as a therapeutic approach. In fact, magnesium at a dose sufficient to raise the plasma concentration more than two-fold only slightly suppressed thermoregulatory defenses against hypothermia compared with those treated with placebo. The shivering threshold in volunteers given magnesium decreased by only 0.3℃ to a core temperature of 36.3℃ \[[@B3],[@B28]\]. This decrease in core temperature may be mediated by the ability of MgSO~4~ to induce peripheral vasodilatation.

The search continues for anesthetic agents that can sufficiently enhance thermoregulatory tolerance without simultaneously producing other complications \[[@B29]\]. Administration of MgSO~4~ is a potential candidate in this field. However, our results regarding thermoregulatory effects of MgSO~4~ require further investigation, including studies with a larger sample size and different magnesium dosages. Perhaps then a correlation between MgSO~4~ thermoregulatory and shivering effects and spinal anesthesia will be discovered. The duration of anti-shivering effects may be extended by use of higher dosages. Also, we recommend recording core temperature simultaneously with shivering measurement.
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Demographic Data and Basal Variables of the MgSO~4~ and Control Groups
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All parameters are expressed as Mean ± SD. There are no significant differences between them. MgSO~4~: Magnesium sulphate.
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Sedation Rates in the MgSO~4~ and Control Groups
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All parameters are expressed as Numbers. There are no significant differences between them. Parenthesis show percent of them (%). MgSO~4~: Magnesium sulphate.
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Appearance of Shivering after Blocking in the MgSO~4~ and Control Groups
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All parameters are expressed as numbers. There are significant differences between them in 10, 15 and 20 minutes. MgSO~4~: Magnesium sulphate.
